Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Details Narrative)

v3.20.2
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Research and development costs $ 87,000 $ 110,000
Common Stock Options [Member]        
Antidilutive securities excluded from computation of net loss per share, amount     11,715,480 8,515,480
Common Stock Warrants [Member]        
Antidilutive securities excluded from computation of net loss per share, amount     1,153,845 5,337,345
Conversion of Debentures [Member]        
Antidilutive securities excluded from computation of net loss per share, amount     1,650,000 1,650,000
Conversion of shares     52,180,859  
Conversion price per share $ 0.079 $ 0.082 $ 0.079 $ 0.082
Conversion of Redeemable Convertible Preferred Stock [Member]        
Antidilutive securities excluded from computation of net loss per share, amount     7,569,210 41,984,478
Conversion of shares       6,000,000